Form SC 13G/A Transcode Therapeutics, Filed by: 3i, LP
TransCode Therapeutics, Inc. (RNAZ)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
RNAZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAZ alerts
High impacting TransCode Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAZ
News
- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its price target raised by analysts at HC Wainwright from $3.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical TrialPR Newswire
- TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock SplitGlobeNewswire
- TransCode Therapeutics, Inc. Announces $8 Million Private Placement [Yahoo! Finance]Yahoo! Finance
RNAZ
Sec Filings
- 12/20/24 - Form 8-K
- 12/19/24 - Form PRE
- 12/18/24 - Form EFFECT
- RNAZ's page on the SEC website